RecruitingNCT05282277
Estradiol and brain responses to reward during perimenopause
About this title
Read the official source — NCT05282277Medication studyAges 45–55United StatesSchizophrenia
Understand this study
Who could participate?
Listed age limits: 45 years to 55 years.
- Listed locations
- Chapel HillSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 20, 2022
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 103
- Sponsor
- University of North Carolina, Chapel Hill
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 45 Years to 55 Years
- Official registry ID
- NCT05282277
- Official title
Show the full official title
Examining the Effects of Estradiol on Neural and Molecular Response to Rewards in Perimenopausal-Onset Anhedonia and Psychosis
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Chapel Hill
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of North Carolina, Chapel Hill, a university.
Does this study involve medication?
Yes. The study involves medication, including Transdermal Estradiol, Micronized Progesterone, Matching Placebo Patch and Raclopride C11.
Who can participate?
Listed age limits: 45 years to 55 years.
Is this study still recruiting?
The registry lists this study as recruiting.
